Curis Inc. Unveils Exciting Findings at the 30th Annual SNO Meeting
Curis, Inc. (NASDAQ: CRIS), a prominent biotech firm, has announced its participation in the upcoming 30th Annual Meeting of the Society for Neuro-Oncology (SNO), which will take place from November 19 to 23, 2025. The company is set to present groundbreaking clinical and preclinical data on its innovative IRAK4 inhibitor, emavusertib (CA-4948), specifically targeting Primary CNS Lymphoma (PCNSL) and Secondary CNS Lymphoma (SCNSL).
The significance of this event lies in the company's planned presentations, which will include three noteworthy discussions and an oral presentation highlighting preclinical findings. On November 21, Dr. Christian Grommes from the Memorial Sloan Kettering Cancer Center in New York will deliver a poster presentation titled "Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination." This presentation aims to elucidate the genetic factors influencing therapeutic outcomes among patients undergoing treatment with emavusertib in combination with Bruton’s tyrosine kinase inhibitor (BTKi).
Additionally, Dr. Lakshmi Nayak from the Dana-Farber Cancer Institute will present preliminary safety and efficacy results of emavusertib combined with ibrutinib in patients with relapsed or refractory PCNSL. This will further illuminate the potential benefits of this combination therapy in challenging cases.
Highlighting the growing interest in emavusertib, a rapid oral presentation by Dr. Grommes will again cover its effects on CNS pharmacokinetics, alongside a poster by Cecilia A. Merrigan from Mayo Clinic discussing the promising efficacy signals for SCNSL patients treated with the same combination.
The culmination of these presentations reflects Curis's commitment to advancing the understanding of treatment options available for patients dealing with aggressive CNS lymphomas. Emavusertib has shown immense potential in previous studies, leading to its designation as an Orphan Drug by the FDA, signaling significant unmet medical need in treating PCNSL and other disorders.
Curis’s innovative approach, particularly in its collaboration with Aurigene Discovery Technologies Limited for the exclusive development of emavusertib, represents a promising frontier in oncology research. The results to be shared at the SNO meeting are anticipated to ignite further discussion in the field and may lead to new treatment paradigms.
Attendees of the SNO meeting are encouraged to engage with Curis as the company showcases its commitment to transforming modern cancer therapies through rigorous scientific inquiry and innovation. For further updates and insights from the presentations, visit Curis's official website at www.curis.com. By presenting this crucial data, Curis not only highlights its pioneering work in biotechnology but also contributes to the collective effort to enhance patient care in oncology, especially for those battling CNS lymphomas.
The significance of this event lies in the company's planned presentations, which will include three noteworthy discussions and an oral presentation highlighting preclinical findings. On November 21, Dr. Christian Grommes from the Memorial Sloan Kettering Cancer Center in New York will deliver a poster presentation titled "Analysis of Genetic Mutation Profile and CNS Pharmacokinetics in Relapsed/Refractory Primary CNS Lymphoma Patients Responding to Novel Emavusertib (IRAK4i) and BTKi Combination." This presentation aims to elucidate the genetic factors influencing therapeutic outcomes among patients undergoing treatment with emavusertib in combination with Bruton’s tyrosine kinase inhibitor (BTKi).
Additionally, Dr. Lakshmi Nayak from the Dana-Farber Cancer Institute will present preliminary safety and efficacy results of emavusertib combined with ibrutinib in patients with relapsed or refractory PCNSL. This will further illuminate the potential benefits of this combination therapy in challenging cases.
Highlighting the growing interest in emavusertib, a rapid oral presentation by Dr. Grommes will again cover its effects on CNS pharmacokinetics, alongside a poster by Cecilia A. Merrigan from Mayo Clinic discussing the promising efficacy signals for SCNSL patients treated with the same combination.
The culmination of these presentations reflects Curis's commitment to advancing the understanding of treatment options available for patients dealing with aggressive CNS lymphomas. Emavusertib has shown immense potential in previous studies, leading to its designation as an Orphan Drug by the FDA, signaling significant unmet medical need in treating PCNSL and other disorders.
Curis’s innovative approach, particularly in its collaboration with Aurigene Discovery Technologies Limited for the exclusive development of emavusertib, represents a promising frontier in oncology research. The results to be shared at the SNO meeting are anticipated to ignite further discussion in the field and may lead to new treatment paradigms.
Attendees of the SNO meeting are encouraged to engage with Curis as the company showcases its commitment to transforming modern cancer therapies through rigorous scientific inquiry and innovation. For further updates and insights from the presentations, visit Curis's official website at www.curis.com. By presenting this crucial data, Curis not only highlights its pioneering work in biotechnology but also contributes to the collective effort to enhance patient care in oncology, especially for those battling CNS lymphomas.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.